Do Not Discontinue Spironolactone Based on Dizziness Alone
Dizziness is a recognized side effect of spironolactone (occurring in 3-4% of patients), but it does not automatically warrant discontinuation after 2 months of therapy. 1 The critical next step is to check blood pressure, serum potassium, and renal function to determine the underlying cause and guide management.
Immediate Evaluation Required
Before making any decision about discontinuation, you must assess:
- Blood pressure measurement - both sitting and standing to evaluate for symptomatic hypotension or orthostatic changes 2
- Serum potassium level - hyperkalemia can cause dizziness and requires immediate attention 3, 4, 2
- Serum creatinine - worsening renal function may contribute to symptoms 3, 4
- Volume status - excessive diuresis can cause dehydration and dizziness 2
Management Algorithm Based on Findings
If Hyperkalemia is Present (K+ >5.5 mmol/L):
- Halve the dose to 25 mg on alternate days and monitor closely 3, 4
- If K+ ≥6.0 mmol/L: Stop immediately and treat hyperkalemia 3, 4
- Recheck potassium within 1 week 2
If Symptomatic Hypotension is Present:
- Consider dose reduction rather than complete discontinuation 5
- Space out medications to reduce synergistic hypotensive effects 5
- Ensure adequate hydration 2
- If on heart failure therapy: continue SGLT2 inhibitors and consider adjusting other agents first (ACEi/ARB/beta-blockers) before stopping spironolactone 5
If Worsening Renal Function (Creatinine >220 μmol/L or 2.5 mg/dL):
- Halve the dose to 25 mg on alternate days 3, 4
- If creatinine >310 μmol/L (3.5 mg/dL): Stop immediately 3, 4
If All Parameters are Normal:
- Continue spironolactone at current dose 1
- The dizziness may be transient and unrelated to the medication
- Consider non-pharmacological interventions: compression stockings, increased fluid intake, avoiding rapid position changes 5
Context-Specific Considerations
For heart failure patients: Spironolactone provides mortality benefit and should be maintained whenever possible 3, 6. Discontinuation is associated with 2-4 fold higher risk of adverse events 5. Serial monitoring is mandatory but dizziness alone is not sufficient reason to stop 3, 4.
For acne/hyperandrogenism patients: Dizziness occurs in 3-4% of patients but rarely requires discontinuation 1, 7. In young healthy women without cardiovascular or renal disease, the medication is generally well-tolerated 7. Most side effects are dose-dependent, so dose reduction is preferable to complete cessation 1.
Common Pitfall to Avoid
Do not discontinue spironolactone prematurely without objective assessment. The FDA label confirms that dizziness can occur with overdosage or as a side effect 2, but this is manageable with dose adjustment in most cases. Research shows that side effects in clinical practice are more common than in trials (25% withdrawal rate in one study) 8, but most are related to hyperkalemia or renal dysfunction—both of which are detectable and manageable with monitoring.
The timing (dizziness starting at 2 months) does not follow the typical pattern of immediate medication-related side effects, suggesting the need to rule out other causes before attributing symptoms solely to spironolactone.